Get the Weekly Intelligence Brief — top committee picks every Sunday.

ACAD vs BLLN

ACADIA Pharmaceuticals Inc. vs BillionToOne, Inc. — AI-powered side-by-side comparison
ACAD
ACADIA Pharmaceuticals Inc.
69
Buy
VS
BLLN
BillionToOne, Inc.
59
Watch
MetricACADBLLN
AI Score 69 59
Price $29.41 $97.89
P/E Ratio 13.07× 141.92×
ROE 31.9% 1.6%
Revenue Growth YoY
Gross Margin 91.1% 71.3%
Debt / Equity 0.06× 0.27×
Dividend Yield 0.0% 0.0%
RSI (14) 78.4 30.9
Beta 0.845 0.3401
Expected Upside

AI Committee View

Current Innellis committee reasoning for ACAD versus BLLN.
ACAD leads by 10 points.

ACAD scores 69/100 (Buy) versus BLLN at 59/100 (Watch).

ACAD Committee View
83% agreement
6 analysts

The primary driver is revenue growing 47.0% yoy -- genuine top-line momentum. The main limiting factor is bollinger bandwidth of 24.3% signals elevated volatility. The committee is constructive but not yet at full conviction.

Bull Case
  • P/E of 13.2 is inexpensive for the broad market — Value
  • ROE of 32.4% shows genuine earnings power backing the valuation — Value
  • Revenue growing 47.0% YoY -- genuine top-line momentum — Growth
Bear Case
  • RSI at 78 is in overbought territory — Technical
  • Weekly RSI at 80 -- overbought on the larger timeframe too — Technical
  • Bollinger bandwidth of 24.3% signals elevated volatility — Risk
BLLN Committee View
40% agreement
5 analysts

The committee is genuinely divided. Macro Analyst sees a compelling case — vix regime is low -- calm backdrop supports risk-taking. Value Analyst remains cautious — p/e of 123.4 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.

Bull Case
  • Price structure making higher highs and higher lows — Technical
  • Trend and market structure agree -- coherent bullish picture — Technical
  • Weekly trend (uptrend) confirms the daily trend -- multi-timeframe agreement — Technical
Bear Case
  • P/E of 123.4 is expensive by classic value standards — Value
  • Price-to-book of 7.8x prices in significant intangible value — Value
  • MACD histogram negative -- bearish momentum — Technical
Want the full breakdown?
Committee votes, technicals, and trade plans for both companies.
ACAD Full Analysis BLLN Full Analysis